Abstracts

Reduced Immune Activation During Tenofovir-Emtricitabine Therapy in HIV-Negative Individuals

Background: Higher levels of immune activation are associated with an increased risk of HIV acquisition. Previous research in vitro has identified immunomodulatory properties of tenofovir (TFV) in various cell lines. However, it is unknown whether TFV influences immune activation in vivo. We aimed to evaluate the effects of TFV therapy on cellular immune activation in…

Sevelamer Does Not Decrease Plasma LPS or sCD14 but Does Decrease Soluble Tissue Factor and LDL

Background: Inflammation is associated with increased morbidity and mortality in HIV-infected individuals. Microbial translocation may be a major driver of this inflammation. Sevelamer carbonate, a phosphate binder, decreases serum lipopolysaccharide (LPS), low-density lipoprotein (LDL) cholesterol, and inflammatory markers in hemodialysis patients. We hypothesized that sevelamer would reduce circulating LPS and monocyte and T cell activation…

Rosuvastatin Reduces Immune*Activation and Inflammation in Treated HIV Infection

Background: Despite suppressive antiretroviral therapy (ART), elevated levels of immune activation and inflammation often persist in HIV-infected subjects. Statins have anti-inflammatory effects, and when given in combination with ART, may reduce immune activation. Methodology: The 96-week Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV (SATURN-HIV) trial is a randomized, double-blind, placebo-controlled trial to…

Effects of Prednisolone on CD4 Counts and HIV Disease Progression: A Two-Year Clinical Trial

Background: HIV infection is associated with chronic immune activation, which may be a central mediator of HIV pathogenesis. Here we investigated the effect of the anti-inflammatory corticosteroid prednisolone on HIV disease progression. Methodology: We conducted a randomized, double-blinded, placebo-controlled two-year clinical study in Tanzania to assess the effects of prednisolone on HIV disease progression in…

Mesalamine to Reduce Immune Activation During HIV Infection: A Randomized Controlled Trial

Background: Immune activation predicts morbidity and mortality in treated HIV infection and may contribute to persistent gut epithelial barrier defects and systemic microbial translocation. We hypothesized that the luminally active anti-inflammatory agent, mesalamine, might decrease mucosal inflammation in treated HIV infection, leading to decreases in microbial translocation and systemic immune activation. Methodology: We performed a…

Reduction of sCD163 SP and PD1+ Th Cells Levels in a Phase 1B trial of the NK1R Antagonist Aprepitant

Background: Substance P (SP) is an undecapeptide produced in neurons and immune cells and involved in nociception and inflammation. The effects of SP are mediated by the neurokinin 1 receptor (NK1R). Increased levels of SP are present in HIV-infected individuals and NK1R antagonists have anti-HIV effects in monocyte-derived macrophages in vitro, by decreasing the expression…

Decreased Levels of D-dimer After Probiotic Supplementation in Patients Receiving ART

Background: Despite efficient antiretroviral treatment (ART) HIV-infected patients have increased morbidity and mortality compared to HIV seronegative individuals. Gut microbiota composition has potential impact on HIV pathogenesis and cardiovascular risk. Notably, markers of inflammation, coagulation and microbial translocation have been reported to predict all-cause mortality. The aim of this study was to assess the efficacy…

Rifaximin Has Marginal Impact on Immune Activation in Immune Non-responders to ART – ACTG 5286

Background: Immune activation (%CD38+HLA-DR+ on CD8+ T-cells) predicts disease progression in untreated HIV-1 infection & CD4+ T-cell rise with ART. Immune activation is associated with elevated markers of gut microbial translocation (MT) from HIV-induced gut mucosal CD4+ T-cell depletion. HIV+ persons with CD4+ T-cell 96 weeks with CD4+ T-cell < 350 cells/ mm3 and viral…